Works Cited

1. Centers for Disease Control and Prevention. Vision Health Initiative. Available at Last accessed November 9, 2020.

2. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States.Arch Ophthalmol. 2004;122(4):477-485.

3. Rowe S, MacLean CH, Shekelle PG. Preventing visual loss from chronic eye disease in primary care: scientific review. JAMA. 2004;291(12):1487-1495.

4. Owens PL, Mutter R. Emergency department visits related to eye injuries. Statistical Brief #112. Rockville, MD: Agency for Healthcare Research and Quality; 2011.

5. American Academy of Ophthalmology. Eye Health Statistics. Available at Last accessed November 9, 2020.

6. Wittenborn JS, Rein DB. Cost of Vision Problems: The Economic Burden of Vision Loss and Eye Disorders in the United States. Available at Last accessed November 10, 2020.

7. Wittenborn JS, Zhang X, Feagan CW, et al. The economic burden of vision loss and eye disorders among the United States population younger than 40 years. Ophthalmology. 2013;120(9):1728-1735.

8. American Academy of Ophthalmology. ONE Network: Preferred Practice Patterns. Available at Last accessed November 9, 2020.

9. Kemper AR, Clark SJ. Preschool vision screening in pediatric practices. Clin Pediatr. 2006;45(3):263-266.

10. Castanes MS. Major review: the underutilization of vision screening (for amblyopia, optical anomalies and strabismus) among preschool age children. Binocul Vis Strabismus Q. 2003;18(4):217-232.

11. Hered RW, Wood DL. Preschool vision screening in primary care pediatric practice. Public Health Rep. 2013;128(3):189-197.

12. Rogers GL, Olson Jordan C. Pediatric vision screening. Pediatr Rev. 2013;34(3):126-132.

13. Chou CF, Barker LE, Crews JE, et al. Disparities in eye care utilization among the United States adults with visual impairment: findings from the Behavioral Risk Factor Surveillance System 2006–2009. Am J Opthalmol. 2012;154(6 Suppl):S45-S52.

14. Bourne RR, Stevens GA, White RA, et al. Causes of vision loss worldwide, 1990: a systematic analysis. Lancet Glob Health. 2013;1(6):e339-e349.

15. McGwin G Jr, Xie A, Owsley C. Rate of eye injury in the United States. Arch Ophthalmol. 2005;123(7):970-976.

16. Fraunfelder FW, Fraunfelder FT. Adverse ocular drug reactions recently identified by the National Registry of Drug-Induced Ocular Side Effects. Ophthalmology. 2004;111(7):1275-1279.

17. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications: recognition and management. Drugs. 2007;67(1):75-93.

18. Li J, Tripathi RC, Tripathi BJ. Drug-induced ocular disorders. Drug Saf. 2008;31(2):127-141.

19. Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs. 2010;24(6):501-526.

20. Wilkinson JT, Fraunfelder FW. Use of herbal medicines and nutritional supplements in ocular disorders: an evidence-based review. Drugs. 2011;71(18):2421-2434.

21. Gray H. Gray's Anatomy: Descriptive and Surgical. New York, NY: Cosimo Classics; 2011.

22. Mafee MF, Karimi A, Shah JD, Rapoport M, Ansari SA. Anatomy and pathology of the eye: role of MR imaging and CT. Magn Reson Imaging Clin North Am. 2006;14(2):249-270.

23. McIlwain JT. An Introduction to the Biology of Vision. Cambridge: Cambridge University Press; 1996.

24. Moses K, Banks JC, Nava PB, Petersen D. Atlas of Clinical Gross Anatomy. 2nd ed. Philadelphia, PA: Saunders; 2012.

25. American Optometric Association. Comprehensive Adult Eye and Vision Examination. Available at Last accessed November 10, 2020.

26. U.S. Preventive Services Task Force. Vision screening for children 1 to 5 years of age: U.S. Preventive Services Task Force Recommendation Statement. Pediatrics. 2011;127:340-346.

27. American Optometric Association. Pediatric Eye and Vision Examination. Available at Last accessed November 10, 2020.

28. U.S. Preventive Services Task Force. Screening for impaired visual acuity in older adults: U.S. Preventive Services Task Force recommendation statement. JAMA. 2016;315(9):915-933.

29. Wagner LD, Rein DB. Attributes associated with eye care use in the United States: a meta-analysis. Ophthalmology. 2013;120(7)1497-1501.

30. Centers for Disease Control and Prevention. The State of Vision, Aging, and Public Health in America. Atlanta, GA: U.S. Department of Health and Human Services; 2011.

31. Zhang X, Beckles GL, Chou CF, et al. Socioeconomic disparity in use of eye care services among U.S. adults with age-related eye diseases: National Health Interview Survey, 2002 and 2008. JAMA Ophthalmol. 2013;131(9):1198-1206.

32. Li YJ, Xirasagar S, Pumkam C, Krishnaswamy M, Bennett CL. Vision insurance, eye care visits, and vision impairment among working-age adults in the United States. JAMA Ophthalmol. 2013;131(4):499-506.

33. Kemper AR, Clark SJ. Preschool vision screening by family physicians. J Pediatr Ophthalmol Strabismus. 2007;44(1):24-27.

34. Su Z, Marvin EK, Wang BQ, et al. Identifying barriers to follow-up eye care for children after failed vision screening in a primary care setting. J AAPOS. 2013;17(4):385-390.

35. Wickstrom GC, Kelley DK, Keyserling TC, et al. Confidence of academic general internists and family physicians to teach ambulatory procedures. J Gen Intern Med. 2000;15(6):353-360.

36. Bonds DE, Mychaleckyj JC, Watkins R, Palla S, Extrom P. Ambulatory care skills: do residents feel prepared? Med Educ Online. 2002;7.

37. American Academy of Ophthalmology. Joint Policy Statement: Vision Screening for Infants and Children—2013. Available at Last accessed November 10, 2020.

38. Goldzweig CL, Rowe S, Wenger NS, MacLean CH, Shekelle PG. Preventing and managing visual disability in primary care: clinical applications. JAMA. 2004;291(12):1497-1502.

39. McGee S. Evidence-Based Physical Diagnosis. 3rd ed. Philadelphia, PA: Saunders; 2012.

40. American Academy of Ophthalmology. ONE Network: Clinical Statements. Available at Last accessed November 9, 2020.

41. Committee on Practice and Ambulatory Medicine, Section on Ophthalmology; American Association of Certified Orthoptists; American Association for Pediatric Ophthalmology and Strabismus; American Academy of Ophthalmology. Eye examination in infants, children, and young adults by pediatricians. Pediatrics. 2003;111(4):902-907.

42. Friedman LS, Kaufman LM. Guidelines for pediatrician referrals to the ophthalmologist. Pediatr Clin North Am. 2003;50(1):41-53.

43. Kempen JH, Mitchell P, Lee KE, et al. The prevalence of refractive errors among adults in the United States, Western Europe, and Australia. Arch Ophthalmol. 2004;122(4):495-505.

44. Wen G, Tarczy-Hornoch K, McKean-Cowdin R, et al. Prevalence of myopia, hyperopia, and astigmatism in non-Hispanic white and Asian children: Multi-ethnic Pediatric Eye Disease Study. Ophthalmology. 2013;120(10):2109-2116.

45. Borchert MS, Varma R, Cotter SA, et al. Risk factors for hyperopia and myopia in preschool children the Multi-ethnic Pediatric Eye Disease and Baltimore Pediatric Eye Disease studies. Ophthalmology. 2011;118(10):1966-1973.

46. Ying GS, Maguire MG, Cyert LA, et al. Prevalence of vision disorders by racial and ethnic group among children participating in Head Start. Ophthalmology. 2014;121(3):630-636.

47. Fozailoff A, Traczy-Hornoch K, Cotter S, et al. Prevalence of astigmatism in 6- to 72-month-old African American and Hispanic children: the Multi-ethnic Pediatric Eye Disease Study. Ophthalmology. 2011;118(2):284-293.

48. McKean-Cowdin R, Cotter SA, Tarczy-Hornoch K, et al. Prevalence of amblyopia or strabismus in Asian and non-Hispanic white preschool children: Multi-ethnic Pediatric Eye Disease Study. Ophthalmology. 2013;120(10):2117-2124.

49. Tarczy-Hornoch K, Varma R, Cotter SA, et al. Risk factors for decreased visual acuity in preschool children: the Multi-ethnic Pediatric Eye Disease and Baltimore Pediatric Eye Disease studies. Ophthalmology. 2011;118(11):2262-2273.

50. Naradzay J, Barish RA. Approach to ophthalmologic emergencies. Med Clin North Am. 2006;90(2):305-328.

51. Peate WF. Work-related eye injuries and illnesses. Am Fam Physician. 2007;75(7):1017-1022.

52. Thanathanee O, O'Brien TP. Conjunctivitis: systematic approach to diagnosis and therapy. Curr Infect Dis Rep. 2011;13(2):141-148.

53. Taukikewa M, Stacey AW. A review of hypertensive retinopathy and chorioretinopathy. Clin Optom (Auckl). 2020; [Epub ahead of print].

54. Sambursky R, Tauber S, Schirra F, Kozich K, Davidson R, Cohen EJ. The RPS adeno detector for diagnosing adenoviral conjunctivitis. Ophthalmology. 2006;113(10):1758-1764.

55. Sheikh A, Hurwitz B, van Schayck CP, McLean S, Nurmatov U. Antibiotics versus placebo for acute bacterial conjunctivitis. Cochrane Database Syst Rev. 2012;9:CD001211.

56. Porter RS, Kaplan JL, Homeier BP (eds). The Merck Manual of Patient Symptoms. Whitehouse Station, NJ: Merck Research Laboratories; 2008.

57. Pachigolla G, Blomquist P, Cavanagh HD. Microbial keratitis pathogens and antibiotic susceptibilities: a 5-year review of cases at an urban county hospital in north Texas. Eye Contact Lens. 2007;33(1):45-49.

58. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008;27(1):22-27.

59. Beers MH, Porter RS, Jones TV, Kaplan JL, Berkwits M (eds). The Merck Manual. 19th ed. Whitehouse Station, NJ: Merck Research Laboratories, 2011.

60. Collier SA, Gronostaj MP, MacGurn AK, et al. Estimated burden of keratitis—United States, 2010. MMWR. 2014;63(45):1027-1030.

61. Centers for Disease Control and Prevention. Nearly One Million Doctor Visits for Eye Infections Annually in U.S. Available at Last accessed November 10, 2020.

62. American Academy of Ophthalmology. Red Eye. Available at Last accessed November 10, 2020.

63. Mills DM, Bodman MG, Meyer DR, Morton AD 3rd. The microbiologic spectrum of dacryocystitis: a national study of acute versus chronic infection. Ophthal Plast Reconstr Surg. 2007;23(4):302-306.

64. Kubo M, Sakuraba T, Arai Y, Nakazawa M. Dacryocystorhinostomy for dacryocystitis caused by methicillin-resistant Staphylococcus aureus: report of four cases. Jpn J Ophthalmol. 2002;46(2):177-182.

65. Kotlus BS, Rodgers IR, Udell IJ. Dacryocystitis caused by community-onset methicillin-resistant Staphylococcus aureus. Ophthal Plast Reconstr Surg. 2005;21(5):371-375.

66. Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the Multicenter Uveitis Steroid Treatment Trial. Ophthalmology. 2011;118(10):1916-1926.

67. Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-Up Study Research Group. Association between long-lasting intravitreous flucinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017;317(19):1993-2005.

68. Jackson TL, Paraskevopoulos T, Georgalas I. Systematic review of 342 cases of endogenous bacterial endophthalmitis. Surv Ophthalmol. 2014;59(6):627-635.

69. Pijl BJ, Theelen T, Tilanus MA, Rentenaar R, Crama N. Acute endophthalmitis after cataract surgery: 250 consecutive cases treated at a tertiary referral center in the Netherlands. Am J Ophthalmol. 2010;149(3):482-487.

70. Essex RW, Yi Q, Charles PG, Allen PJ. Post-traumatic endophthalmitis. Ophthalmology. 2004;111(11):2015-2022.

71. Callegan MC, Engelbert M, Parke DW 2nd, Jett BD, Gilmore MS. Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev. 2002;15(1):111-124.

72. Gower EW, Lindsley K, Tulenko SE, Nanji AA, Leyngold I, McDonnell PJ. Perioperative antibiotics for prevention of acute endophthalmitis after cataract surgery. Cochrane Database Syst Rev. 2017;2:CD006364.

73. Kim CH, Chen ME, Coleman AL. Adjunctive steroid therapy versus antibiotics alone for acute endophthalmitis after intraocular procedure. Cochrane Database Syst Rev. 2017;2:CD012131.

74. Sivaraj RR, Durrani OM, Denniston AK, Murray PI, Gordon C. Ocular manifestations of systemic lupus erythematosus. Rheumatology (Oxford). 2007;46(12):1757-1762.

75. Anshu A, Chee SP. Posterior scleritis and its association with HLA B27 haplotype. Ophthalmologica. 2007;221(4):275-278.

76. Atkins EJ, Biousse V, Newman NJ. The natural history of optic neuritis. Rev Neurol Dis. 2006;3(2):45-56.

77. Morales DS, Siatkowski RM, Howard CW, Warman R. Optic neuritis in children. J Pediatr Ophthalmol Strabismus. 2000;37(5): 254-259.

78. Sathappan VS. Childhood Optic Neuritis. Available at Last accessed November 10, 2020.

79. Bonhomme GR, Waldman AT, Balcer LJ, et al. Pediatric optic neuritis: brain MRI abnormalities and risk of multiple sclerosis. Neurology. 2009;72(10):881-885.

80. Gal RL, Vedula SS, Beck R. Corticosteroids for treating optic neuritis. Cochrane Database Syst Rev. 2015;8:CD001430.

81. Optic Neuritis Study Group. Visual function 15 years after optic neuritis: a final follow-up report from the Optic Neuritis Treatment Trial. Ophthalmology. 2008;115(6):1079-1082.

82. Wilejto M, Shroff M, Buncic JR, Kennedy J, Goia C, Banwell B. The clinical features, MRI findings, and outcome of optic neuritis in children. Neurology. 2006;67(2):258-262.

83. Brady KM, Brar AS, Lee AG, Coats DK, Paysse EA, Steinkuller PG. Optic neuritis in children: clinical features and visual outcome. J AAPOS. 1999;3(2):98-103.

84. Lindsley K, Matsumura S, Hatef E, Akpek EK. Interventions for chronic blepharitis. Cochrane Database Syst Rev. 2012;5:CD005556.

85. Lindsley K, Nichols JJ, Dickersin K. Interventions for acute internal hordeolum. Cochrane Database Syst Rev. 2017;1:CD007742.

86. U.S. Food and Drug Administration. FDA Approves New Medication for Dry Eye Disease. Available at Last accessed November 10, 2020.

87. Ervin A-M, Law A, Pucker AD. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev. 2017;6:CD006775.

88. American Academy of Ophthalmology. Choosing Wisely: Five Things Ophthalmologists and Patients Should Question. Available at Last accessed November 10, 2020.

89. Piskiniene R. Eyelid malposition: lower lid entropion and ectropion. Medicina (Kaunas). 2006;42(11):881-884.

90. Skorin L Jr. A review of entropion and its management. Cont Lens Anterior Eye. 2003;26(2):95-100.

91. Mitchell P, Hinchcliffe P, Wang JJ, Rochtchina E, Foran S. Prevalence and associations with ectropion in an older population: the Blue Mountains Eye Study. Clin Experiment Ophthalmol. 2001;29(3):108-110.

92. DeAngelis DD, Carter SR, Seiff SR. Dermatochalasis. Int Ophthalmol Clin. 2002;42(2):89-101.

93. Morris CL, Chesnutt DA. Acquired Ptosis Evaluation and Management. Available at Last accessed November 10, 2020.

94. Scheinfeld N. The use of apraclonidine eyedrops to treat ptosis after the administration of botulinum toxin to the upper face. Dermatol Online J. 2005;11(1):9.

95. Popovic Suic S, Cerovski B, Tojagic M. Lid retraction etiology. Acta Med Croatica. 2004;58(5):407-409.

96. Aldave AJ, Maus M, Rubin PA. Advances in the management of lower eyelid retraction. Facial Plast Surg. 1999;15(3):213-224.

97. Hallett M, Evinger C, Jankovic J, Stacy M. Update on blepharospasm: report from the BEBRF International Workshop. Neurology. 2008;71:1275-1282.

98. Peckham EL, Lopez G, Shamim EA, et al. Clinical features of patients with blepharospasm: a report of 240 patients. Eur J Neurol. 2011;18(3):382-386.

99. Vaziri K, Schwartz SG, Flynn HW Jr, Kishor KS, Moshfeghi AA. Eye-related emergency department visits in the United States, 2010. Ophthalmology. 2016;123(4):917-919.

100. Brophy M, Sinclair SA, Hosteteler SG, Xiang H. Pediatric eye injury-related hospitalizations in the United States. Pediatrics. 2006;117(6):1263-1271.

101. McGwin G Jr, Hall TA, Xie A, Owsley C. Trends in eye injury in the United States, 1992–2001. Invest Ophthalmol Vis Sci. 2006;47(2):521-527.

102. Blackburn J, Levitan EB, MacLennan PA, Owsley C, McGwin G Jr. The epidemiology of chemical eye injuries. Curr Eye Res. 2012;37(9):787-793.

103. Chen AJ, Linakis JG, Mello MJ, Greenberg PB. Epidemiology of infant ocular and periocular injuries from consumer products in the United States, 2001–2008. J AAPOS. 2013;17(3):239-242.

104. Cheung CA, Rogers-Martel M, Golas L, et al. Hospital-based ocular emergencies: epidemiology, treatment, and visual outcomes. Am J Emerg Med. 2014;32(3):221-224.

105. Pollard KA, Xiang H, Smith GA. Pediatric eye injuries treated in U.S. emergency departments, 1990–2009. Clin Pediatr (Phila). 2012;51(4):374-381.

106. Chen AJ, Kim JG, Linakis JG, Mello MJ, Greenberg PB. Eye injuries in the elderly from consumer products in the United States: 2001–2007. Graefes Arch Clin Exp Ophthalmol. 2013;251(3):645-651.

107. American Association for Pediatric Ophthalmology and Strabismus. Eye Safety. Available at Last accessed November 10, 2020.

108. Chen AJ, Chan JJ, Linakis JG, Mello MJ, Greenberg PB. Age and consumer product-related eye injuries in the United States.R I Med J. 2014;97(1):44-48.

109. Moren Cross J, Griffin R, Owsley C, McGwin G. Pediatric eye injuries related to consumer products in the United States, 1997–2006. J AAPOS. 2008;12(6):626-628.

110. McGwin G Jr, Hall TA, Seale J, Xie A, Owsley C. Consumer product-related eye injury in the United States, 1998–2002. J Safety Res. 2006;37(5):501-506.

111. Seidman CJ, Linakis JG, Mello MJ, Greenberg PB. Aerosol container-related eye injuries in the United States: 1997–2009.Am J Ophthalmol. 2011;151(6):1041-1046.

112. Listman DA. Paintball injuries in children: more than meets the eye. Pediatrics. 2004;113(1 Pt 1):e15-18.

113. Pahk PJ, Adelman RA. Ocular trauma resulting from paintball injury. Graefes Arch Clin Exp Ophthalmol. 2009;247(4):469-475.

114. Alliman KJ, Smiddy WE, Banta J, et al. Ocular trauma and visual outcome secondary to paintball projectiles. Am J Ophthalmol. 2009;147(2):239-242.

115. Tu Y. 2019 Fireworks Annual Report. Bethesda, MD: U.S. Consumer Product Safety Commission; 2019.

116. Canner JK, Haider AH, Selvarajah S, et al. U.S. emergency department visits for fireworks injuries, 2006–2010. Surg Res. 2014;190(1):305-311.

117. Witsaman RJ, Comstock RD, Smith GA. Pediatric fireworks-related injuries in the United States: 1990–2003. Pediatrics. 2006;118(1):296-303.

118. American Academy of Ophthalmology. Recognizing and Treating Eye Injuries. Available at Last accessed November 10, 2020.

119. American Academy of Ophthalmology, American Academy of Pediatricians. Joint Policy Statement: Protective Eyewear for Young Athletes. San Francisco, CA: American Academy of Ophthalmology; 2013.

120. Rodriguez JO, Lavina AM, Agarwal A. Prevention and treatment of common eye injuries in sports. Am Fam Physician. 2003;67(7):1481-1488.

121. Khaw PT, Shah P, Elkington AR. Injury to the eye. BMJ. 2004;328(7430):36-38.

122. Kriz PK, Comstock RD, Zurakowski D, et al. Effectiveness of protective eyewear in reducing eye injuries among high school field hockey players. Pediatrics. 2012;130(6):1069-1075.

123. Lincoln AE, Caswell AV, Almquist JL, et al. Effectiveness of the women's lacrosse protective eyewear mandate in the reduction of eye injuries. Am J Sports Med. 2012;40(3):611-614.

124. Forrest KY, Cali JM. Epidemiology of lifetime work-related eye injuries in the U.S. population associated with one or more lost days of work. Ophthalmic Epidemiol. 2009;16(3):156-162.

125. Bureau of Labor Statistics. Nonfatal Occupational Injuries and Illnesses Requiring Days Away From Work, 2015. Available at Last accessed November 10, 2020.

126. Luo H, Beckles GL, Fang X, et al. Socioeconomic status and lifetime risk for workplace eye injury reported by a us population aged 50 years and over. Ophthalmic Epidemiol. 2012;19(2):103-110.

127. Blehm C, Vishnu S, Khattak A, Mitra S, Yee RW. Computer vision syndrome: a review. Surv Ophthalmol. 2005;50(3):253-262.

128. Rosenfield M. Computer vision syndrome: a review of ocular causes and potential treatments. Ophthalmic Physiol Opt. 2011;31(5):502-515.

129. Wolkoff P, Nojgaard JK, Troiano P, Piccoli B. Eye complaints in the office environment: precorneal tear film integrity influenced by eye blinking efficiency. Occup Environ Med. 2005;62:4-12.

130. Wolkoff P, Karcher T, Mayer H. Problems of the "outer eyes" in the office environment: an ergophthalmologic approach. J Occup Environ Med. 2012;54(5):621-631.

131. Occupational Safety and Health Administration. Eye and Face Protection eTool. Available at Last accessed November 10, 2020.

132. Karliner LS, Jacobs EA, Chen AH, Mutha S. Do professional interpreters improve clinical care for patients with limited English proficiency? A systematic review of the literature. Health Serv Res. 2007;42(2):727-754.

133. Kuo DZ, O'Connor KG, Flores G, Minkovitz CS. Pediatricians' use of language services for families with limited English proficiency. Pediatrics. 2007;119(4):920-927.

134. Ngo-Metzger Q, Massagli MP, Clarridge BR, et al. Linguistic and cultural barriers to care. J Gen Intern Med. 2003;18(1):44-52.

135. Pokhrel P, Loftus SA. Ocular emergencies. Am Fam Physician. 2007;76(6):829-836.

136. MedlinePlus. Corneal Ulcers and Infections. Available at Last accessed November 10, 2020.

137. Wipperman JL, Dorsch JN. Evaluation and management of corneal abrasions. Am Fam Physician. 2013;87(2):114-120.

138. Wakai A, Lawrenson JG, Lawrenson AL, et al. Topical non-steroidal anti-inflammatory drugs for analgesia in traumatic corneal abrasions. Cochrane Database Syst Rev. 2017;5:CD009781.

139. Carley F, Carley S. Towards evidence-based emergency medicine: best BETs from the Manchester Royal Infirmary: mydriatics in corneal abrasion. Emerg Med J. 2001;18(4):273.

140. Meek R, Sullivan A, Favilla M, Lamour I, Guastalegname S. Is homatropine 5% effective in reducing pain associated with corneal abrasion when compared with placebo? A randomized controlled trial. Emerg Med Australas. 2010;22(6):507-513.

141. Fraser S. Corneal abrasion. Clin Ophthalmol. 2010;4:387-390.

142. Thiel B, Sarau A, Ng D. Efficacy of topical analgesics in pain control for corneal abrasions: a systematic review. Cureus. 2017;9(3):e1121.

143. Lim CH, Turner A, Lim BX. Patching for corneal abrasion. Cochrane Database Syst Rev. 2016;7:CD004764.

144. Mukherjee P, Sivakumar A, Mackway-Jones K. Tetanus prophylaxis in superficial corneal abrasions. Emerg Med J. 2003;20(1):62-64.

145. Mimura T, Usui T, Yamagami S, et al. Recent causes of subconjunctival hemorrhage. Ophthalmologica. 2010;224(3):133-137.

146. DeRidder CA, Berkowitz CD, Hicks RA, Laskey AL. Subconjunctival hemorrhages in infants and children: a sign of nonaccidental trauma. Pediatr Emerg Care. 2013;29(2):222-226.

147. Gelston CD. Common eye emergencies. Am Fam Physician. 2013;88(8):515-519.

148. Ing E. Eyelid Laceration Treatment and Management. Available at Last accessed November 10, 2020.

149. Kosoko A, Vu Q, Kosoko-Lasaki O. Chemical ocular burns: a case review. Am J Clin Med. 2009;6(3):41-49.

150. Roper-Hall MJ. Thermal and chemical burns. Trans Ophthalmol Soc U K. 1965;85:631-653.

151. Mackway-Jones K, Marsden J. Ascorbate for alkali burns to the eye. Emerg Med J. 2003;20(5):465-466.

152. Acerra JR. Globe Rupture. Available at Last accessed November 10, 2020.

153. Cain W Jr, Sinskey RM. Detection of anterior chamber leakage with Seidel's test. Arch Ophthalmol. 1981;99(11):2013.

154. Pandya HK. Retinal Detachment. Available at Last accessed November 10, 2020.

155. National Institutes of Health. Visual Impairment, Blindness Cases in U.S. Expected to Double By 2050. Available at Last accessed November 10, 2020.

156. Donahue SP. Pediatric strabismus. N Engl J Med. 2007;356(10):1040-1047.

157. Cotter SA, Varma R, Tarczy-Hornoch, et al. Risk factors associated with childhood strabismus: the Multi-ethnic Pediatric Eye Disease and Baltimore Pediatric Eye Disease studies. Ophthalmology. 2011;118(11):2251-2261.

158. Gulati S, Andrews CA, Apkarian AO, et al. Effect of gestational age and birth weight on the risk of strabismus among premature infants. JAMA Pediatr. 2014;168(9):850-856.

159. Jones-Jordan L, Wang X, Scherer RW, Mutti DO. Spectacle correction versus no spectacles for prevention of strabismus in hyperopic children. Cochrane Database Syst Rev. 2014;8:CD007738.

160. Pascual M, Huang J, Maguire MG, et al. Risk factors for amblyopia in the vision in preschoolers study. Ophthalmology. 2014;121(3):622-629.

161. Gunton KB. Advances in amblyopia: what have we learned from PEDIG trials? Pediatrics. 2013;131(3):540-547.

162. Pediatric Eye Disease Investigator Group. Randomized trial of treatment of amblyopia in children aged 7 to 17 years. Arch Ophthalmol. 2005;123(4):437-447.

163. Taylor K, Powell C, Hatt SR, Stewart C. Interventions for unilateral and bilateral refractive amblyopia. Cochrane Database Syst Rev. 2012;4:CD005137.

164. Taylor K, Elliott S. Interventions for strabismic amblyopia. Cochrane Database Syst Rev. 2014;7:CD006461.

165. Li T, Shotton K. Conventional occlusion versus pharmacologic penalization for amblyopia. Cochrane Database Syst Rev. 2009;4:CD006460.

166. Repka MX, Kraker RT, Holmes JM, et al. Atropine vs patching for treatment of moderate amblyopia: follow-up at 15 years of age of a randomized clinical trial. JAMA Ophthalmol. 2014;132(7):799-805.

167. Wallace MP, Stewart CE, Moseley MJ, et al. Compliance with occlusion therapy for childhood amblyopia. Invest Ophthalmol Vis Sci. 2013;54(9):6158-6166.

168. Zhang X, Cotch MF, Ryskulova A, et al. Vision health disparities in the United States by race/ethnicity, education, and economic status: findings from two nationally representative surveys. Am J Ophthalmol. 2012;154(6 Suppl):S53-S62.

169. Hong T, Mitchell P, Burlutsky G, Samarawickrama C, Wang JJ. Visual impairment and the incidence of falls and fractures among older people: longitudinal findings from the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci. 2014;55(11):7589-7593.

170. Feinberg JL, Rogers PA, Sokol-McKay D. Age-related eye disease and medication safety. Ann Longterm Care. 2009;17:17-22.

171. Virgili G, Acosta R, Grover LL, Bentley SA, Giacomelli G. Reading aids for adults with low vision. Cochrane Database Syst Rev. 2013;10:CD003303.

172. Markowitz M. Occupational therapy interventions in low vision rehabilitation. Can J Ophthalmol. 2006;41(3):340-347.

173. Rosenberg EA, Sperazza LC. The visually impaired patient. Am Fam Physician. 2008;77(10):1431-1436.

174. Riaz Y, de Silva SR, Evans JR. Manual small incision cataract surgery (MSICS) with posterior chamber intraocular lens versus phacoemulsification with posterior chamber intraocular lens for age-related cataract. Cochrane Database Syst Rev. 2013;10:CD008813.

175. Moyer VA, on behalf of the U.S. Preventive Services Task Force. Screening for glaucoma: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(7):484-489.

176. Klein R, Klein BE. The prevalence of age-related eye diseases and visual impairment in aging: current estimates. Invest Ophthalmol Vis Sci. 2013;54(14):ORSF5-ORSF13.

177. Klein BE, Klein R. Projected prevalences of age-related eye diseases. Invest Ophthalmol Vis Sci. 2013;54(14):ORSF14-ORSF17.

178. Shaikh Y, Yu F, Coleman AL. Burden of undetected and untreated glaucoma in the United States. Am J Ophthalmol. 2014;158(6):1121-1129.

179. Zhao D, Cho J, Kim MH, Friedman DS, Guallar E. Diabetes, fasting glucose, and the risk of glaucoma: a meta-analysis. Ophthalmology. 2014;158(6):1121-1129.

180. Tehrani S. Gender difference in the pathophysiology and treatment of glaucoma. Curr Eye Res. 2014;6:1-10.

181. Zhao D, Cho J, Kim MH, Guallar E. The association of blood pressure and primary open-angle glaucoma: a meta-analysis. Am J Ophthalmol. 2014;158(3):615-627.

182. Fernandez Lopez E, Karaca EE, Ekici F, Waisbourd M, Spaeth GL. Symptoms reported by patients with varying stages of glaucoma: review of 401 cases. Can J Ophthalmol. 2014;49(5):420-425.

183. Shah NN, Bowd C, Medeiros FA, et al. Combining structural and functional testing for detection of glaucoma. Ophthalmology. 2006;113(9):1593-1602.

184. Boland MV, Ervin AM, Friedman DS, et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;158(4):271-279.

185. American Glaucoma Society. Position Statement on Marijuana and the Treatment of Glaucoma. Available at Last accessed November 10, 2020.

186. Ervin AM, Boland MV, Myrowitz EH, et al. (eds). Screening for glaucoma: comparative effectiveness. AHRQ Comparative Effectiveness Reviews. Rockville, MD: Agency for Healthcare Research and Quality; 2012.

187. Kang JH, Pasquale LR, Willett W, et al. Antioxidant intake and primary open-angle glaucoma: a prospective study. Am J Epidemiol. 2003;158(4):337-346.

188. Chandrasekaran S, Rochtchina E, Mitchell P. Effects of caffeine on intraocular pressure: the Blue Mountains Eye Study. J Glaucoma. 2005;14(6):504-507.

189. Kang JH, Pasquale LR, Willett WC, et al. Dietary fat consumption and primary open-angle glaucoma. Am J Clin Nutr. 2004;79(5):755-764.

190. Bressler SB, Munoz B, Solomon SD, et al. Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project. Arch Ophthalmol. 2008;126(2):241-245.

191. Klein R, Chou CF, Klein BE, et al. Prevalence of age-related macular degeneration in the U.S. population. Arch Ophthalmol. 2011;129(1):75-80.

192. Kawasaki R, Yasuda M, Song SJ, et al. The prevalence of age-related macular degeneration in Asians: a systematic review and meta-analysis. Ophthalmology. 2010;117(5):921-927.

193. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol. 2010;10:31.

194. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age-related macular degeneration—emerging pathogenetic and therapeutic concepts. Ann Med. 2006;38(7):450-471.

195. Wang X, Jiang C, Zhang Y, et al. Role of lutein supplementation in the management of age-related macular degeneration: meta-analysis of randomized controlled trials. Ophthalmic Res. 2014;52(4):198-205.

196. Solomon SD, Lindsley K, Vedula SS, Krzystolik MG, Hawkins BS. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration. Cochrane Database Syst Rev. 2014;8:CD005139.

197. Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW. Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol. 2012;154(2):222-226.

198. Retina Today. Another Anti-VEGF Agent for Treatment of Neovascular AMD. Available at Last accessed November 10, 2020.

199. Ophthalmology Times. Novel Anti-VEGF Agent Approved in China May Reduce Injection Frequency. Available at Last accessed November 10, 2020.

200. Khan JC, Thurlby DA, Shahid H, et al. Smoking and age related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularisation. Br J Ophthalmol. 2006;90(1):75-80.

201. American Academy of Ophthalmology. Ocular Manifestations of Systemic Diseases. Available at Last accessed November 10, 2020.

202. Fong DS, Aiello LP, Gardner TW, et al. Diabetic retinopathy. Diabetes Care. 2003;26(suppl 1):S99-S102.

203. ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010;363(3):233-244.

204. Chew EY, Davis MD, Danis RP, et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: The Action to Control Cardiovascular Risk in Diabetes Eye Study. Ophthalmology. 2014;121(12):2443-2451.

205. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298(8):902-916.

206. American Optometric Association. Clinical Practice Guidelines: Evidence-Based Clinical Practice Guideline Eye Care of the Patient with Diabetes Mellitus. Available at Last accessed November 10, 2020.

207. Fraser-Bell S, Symes R, Vaze A. Hypertensive eye disease: a review. Clin Exp Ophthalmol. 2017;45:45-53.

208. Baker CW, Glassman AR, Beaulieu WT, et al. Effect of initial management with aflibercept vs laser photocoagulation vs observation on vision loss among patients with diabetic macular edema involving the center of the macula and good visual acuity: a randomized clinical trial. JAMA. 2019;321:1880-1894.

209. Leasher JL, Bourne RRA, Flaxman SR, et al. Global estimates on the number of people blind or visually impaired by diabetic retinopathy: a meta-analysis from 1990 to 2010. Diabetes Care. 2016;39:1643-1649.

210. Stewart MW. Critical appraisal of ranibizumab in the treatment of diabetic macular edema. Clin Ophthalmol. 2013;7:1257-1267.

211. International Diabetes Federation. Diabetes Facts and Figures. Available at Last accessed November 9, 2020.

212. Jampol LM, Glassman AR, Sun J. Evaluation and care of patients with diabetic retinopathy. N Engl J Med. 2020;382:1629-1637.

213. American Academy of Ophthalmology. U.S. Eye Disease Statistics. Available at Last accessed November 9, 2020.

214. Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6:CD007419.

215. Lexicomp Online. Available at Last accessed November 10, 2020.

216. Mavrikakis E. Macular Edema in Diabetes. Available at Last accessed November 10, 2020.

217. Zwarenstein M, Shiller SK, Croxford R. Printed educational messages aimed at family practitioners fail to increase retinal screening among their patients with diabetes: a pragmatic cluster randomized controlled trial [ISRCTN72772651]. Implement Sci. 2014;9:87.

218. Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med. 2004;351(22):2310-2317.

219. Wong TY, Klein R, Sharrett AR, et al. The prevalence and risk factors of retinal microvascular abnormalities in older people: the Cardiovascular Health Study. Ophthalmology. 2003;110(4):658-666.

220. Patel SJ, Lundy DC. Ocular manifestations of autoimmune disease. Am Fam Physician. 2002;66(6):991-998.

221. Choudhary MM, Hajj-Ali RA, Lowder CY. Gender and ocular manifestations of connective tissue diseases and systemic vasculitides. J Ophthalmol. 2014;2014:403042.

222. Goldberg DE, Smithen LM, Angelilli A, Freeman WR. HIV-associated retinopathy in the HAART era. Retina. 2005;25(5):633-649.

223. Accorinti M, Pirraglia MP, Corradi R, Corsi C, Fabiani C, Pivetti-Pezzi P. Changing patterns of ocular manifestations in HIV seropositive patients treated with HAART. Eur J Ophthalmol. 2006;16(5):728-732.

224. Thorne JE, Jabs DA, Kempen JH, et al. Incidence of and risk factors for visual acuity loss among patients with AIDS and cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Ophthalmology. 2006;113(8):1432-1440.

225. Jabs DA, Ahuja A, Van Natta M, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: five-year outcomes. Ophthalmology. 2010;117(11):2152-2161.

226. Lai TY, Wong RL, Luk FO, et al. Ophthalmic manifestations and risk factors for mortality of HIV patients in the post-highly active anti-retroviral therapy era. Clin Experiment Ophthalmol. 2011;39(2):99-104.

227. Butler NJ, Thorne JE. Current status of HIV infection and ocular disease. Curr Opin Ophthalmol. 2012;23(6):517-522.

228. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Available at Last accessed November 10, 2020.

229. Gangaputra S, Drye L, Vaidya V, et al. Non-cytomegalovirus ocular opportunistic infections in patients with acquired immunodeficiency syndrome. Am J Ophthalmol. 2013;155(2):206-212.

230. Freeman WR, Van Natta ML, Jabs D, et al. Vision function in HIV-infected individuals without retinitis: report of the Studies of Ocular Complications of AIDS Research Group. Am J Ophthalmol. 2008;145(3):453-462.

231. Kalyani PS, Fawzi AA, Gangaputra S, et al. Retinal vessel caliber among people with acquired immunodeficiency syndrome: relationships with visual function. Am J Ophthalmol. 2012;153(3):428-433.

232. Fraunfelder FW. Ocular side effects from herbal medicines and nutritional supplements. Am J Ophthalmol. 2004;138(4):639-647.

233. Michaelides M, Stover NB, Francis PJ, Weleber RG. Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy. Arch Ophthalmol. 2011;129(1):30-39.

234. Marmor MF, Kellner U, Lai TY, et al. Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Ophthalmology. 2011;118(2):415-422.

235. Browning DJ. Impact of the revised American Academy of Ophthalmology guidelines regarding hydroxychloroquine screening on actual practice. Am J Ophthalmol. 2013;155(3):418-428.

236. Centers for Disease Control and Prevention. Vision Health Initiative (VHI): Four in 10 U.S. Adults Are At High Risk for Vision Loss. Available at Last accessed November 9, 2020.

237. Raman SV, Jacob J. Mydriasis due to Datura inoxia. Emerg Med J. 2005;22:310-311.

238. Ward E, DeSantis C, Robbins A, Kohler B, Jemal A. Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):83-103.

239. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.

240. Ahmad SM, Esmaeli B. Metastatic tumors of the orbit and ocular adnexa. Curr Opin Ophthalmol. 2007;18(5):405-413.

241. National Cancer Institute. Retinoblastoma Treatment (PDQ). Available at Last accessed November 10, 2020.

242. Wong JR, Tucker MA, Kleinerman RA, Devesa SS. Retinoblastoma incidence patterns in the U.S. Surveillance, Epidemiology, and End Results program. JAMA Ophthalmol. 2014;132(4):478-483.

243. Abramson DH, Beaverson K, Sangani P, et al. Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival. Pediatrics. 2003;112(6):1248-1255.

244. AAO Pediatric Ophthalmology/Strabismus PPP Panel, Hoskins Center for Quality Eye Care. Pediatric Eye Evaluations PPP, 2017. Available at Last accessed November 10, 2020.

245. National Cancer Institute. Intraocular (Uveal) Melanoma Treatment (PDQ). Available at Last accessed November 10, 2020.

246. Weis E, Shah CP, Lajous M, Shields JA, Shields CL. The association between host susceptibility factors and uveal melanoma: a meta-analysis. Arch Ophthalmol. 2006;124(1):54-60.

247. Shields CL, Manalac J, Das C, Ferguson K, Shields JA. Choroidal melanoma: clinical features, classification, and top 10 pseudomelanomas. Curr Opin Ophthalmol. 2014;25(3):177-185.

248. Schwartz GG. Eye cancer incidence in U.S. States and access to fluoridated water. Cancer Epidemiol Biomarkers Prev. 2014;23(9):1707-1711.

249. Patel M, Smyth E, Chapman PB, et al. Therapeutic implications of the emerging molecular biology of uveal melanoma. Clin Cancer Res. 2011;17(8):2087-2100.

250. Luke JJ, Triozzi PL, McKenna KC, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res. 2015;28(2):135-147.

251. Harbour JW, Chao DL. A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. Ophthalmology. 2014;121(6):1281-1288.

252. Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25(3):234-239.

253. Davis JL. Intraocular lymphoma: a clinical perspective. Eye (Lond). 2013;27(2):153-162.

254. Gündüz K, Pulido JS, McCannel CA, O'Neill BP. Ocular manifestations and treatment of central nervous system lymphomas. Neurosurg Focus. 2006;21(5):E9.

255. Gangaputra S, Nussenblatt R, Levy-Clarke G. Therapeutic modalities for intraocular lymphoma. Cancer Therapy. 2008;6:131-136.

256. Rajagopal R, Harbour JW. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma. Retina. 2011;31(3):435-450.

257. Chan CC, Wallace DJ. Intraocular lymphoma: update on diagnosis and management. Cancer Control. 2004;11(5):285-295, 317-325.

258. Donaldson MJ, Sullivan TJ, Whitehead KJ, Williamson RM. Squamous cell carcinoma of the eyelids. Br J Ophthalmol. 2002;86(10):1161-1165.

259. Lee PK. Common skin cancers. Minn Med. 2004;87(3):44-47.

260. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin Cancer. Available at Last accessed November 10, 2020.

261. Prabhakaran VC, Gupta A, Huilgol SC, Selva D. Basal cell carcinoma of the eyelids. Compr Ophthalmol Update. 2007;8(1):1-14.

262. Faustina M, Diba R, Ahmadi MA, Esmaeli B. Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma. Ophthalmology. 2004;111(10):1930-1932.

263. Shi Y, Jia R, Fan X. Ocular basal cell carcinoma: a brief literature review of clinical diagnosis and treatment. Onco Targets Ther. 2017;10:2483-2489.

264. Stulberg DL, Crandell B, Fawcett RS. Diagnosis and treatment of basal cell and squamous cell carcinoma. Am Fam Physician. 2005;72(1):1481-1488.

265. Bader RS. Basal Cell Carcinoma. Available at Last accessed November 10, 2020.

266. Rubin AI, Chen EH, Ratner, D. Basal-cell carcinoma. N Engl J Med. 2005;353(21):2262-2269.

267. Margo CE. Eyelid tumors: accuracy of clinical diagnosis. Am J Ophthalmol. 1999;128(5):635-636.

268. Connolly SM, Baker DR, Coldiron BM, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531-550.

269. Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database, part I: periocular basal cell carcinoma experience over 7 years. Ophthalmology. 2004;111(4):624-630.

270. Saydah SH, Gerzoff RB, Saadine JB, et al. Eye care among U.S. adults at high risk for vision loss in the United States in 2002 and 2017. JAMA Ophthalmol. 2020;138:479-489.

271. U.S. Food and Drug Administration. FDA Approves First Biosimilar to Treat Macular Degeneration Disease and Other Eye Conditions. Available at Last accessed October 12, 2021.

Evidence-Based Practice Recommendations Citations

1. American Optometric Association. Comprehensive Adult Eye and Vision Examination. St. Louis, MO: American Optometric Association; 2015. Available at Last accessed November 16, 2020.

2. Wippold FJ II, Cornelius RS, Berger KL, et al. ACR Appropriateness Criteria: Orbits, Vision, and Visual Loss. Reston, VA: American College of Radiology; 2017. Available at Last accessed November 16, 2020.

3. Cincinnati Children's Hospital Medical Center. Best Evidence Statement (BESt): Use of Irrigation Solution, Warm versus Room Temperature, for Irrigation Procedures in the Emergency Department and Urgent Care. Cincinnati, OH: Cincinnati Children's Hospital Medical Center; 2012. Summary retrieved from Guideline Central at Last accessed November 16, 2020.

4. American Academy of Ophthalmology Pediatric Ophthalmology/Strabismus Panel. Amblyopia Preferred Practice Pattern—2017. San Francisco, CA: American Academy of Ophthalmology; 2017. Available at Last accessed November 16, 2020.

5. American Optometric Association. Evidence-Based Clinical Practice Guideline: Eye Care of the Patient with Diabetes Mellitus. 2nd ed. St. Louis, MO: American Optometric Association; 2019. Available at Last accessed November 16, 2020.

Copyright © 2020 NetCE, PO Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.